Regenesis developed and now markets the Provant(R) Wound Therapy System. Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics. For more information about Regenesis Biomedical visit http://www.Regenesisbiomedical.com
About Advanced BioHealing, Inc.
Advanced BioHealing is an industry leader in the science of
regenerative medicine. The Company is focused on the commercialization of
cell-based and tissue-engineered products. It currently markets the
FDA-approved product Dermagraft, for diabetic foot ulcers. Additionally,
the Company's development pipeline includes a next-generation bioengineere
|SOURCE Regenesis Biomedical, Inc.; Advanced BioHealing, Inc.|
Copyright©2008 PR Newswire.
All rights reserved